Walleye Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $12.6M | Buy |
38,715
+36,345
| +1,534% | +$11.9M | 0.05% | 210 |
|
|
2025
Q1 | $640K | Sell |
2,370
-17,746
| -88% | -$4.79M | ﹤0.01% | 987 |
|
|
2024
Q4 | $4.73M | Buy |
20,116
+16,467
| +451% | +$3.87M | 0.01% | 448 |
|
|
2024
Q3 | $1M | Sell |
3,649
-66,658
| -95% | -$18.3M | ﹤0.01% | 1037 |
|
|
2024
Q2 | $17.1M | Buy |
70,307
+23,449
| +50% | +$5.7M | 0.03% | 131 |
|
|
2024
Q1 | $7M | Buy |
46,858
+22,044
| +89% | +$3.29M | 0.01% | 346 |
|
|
2023
Q4 | $4.75M | Buy |
+24,814
| New | +$4.75M | 0.01% | 376 |
|
|
2023
Q3 | – | Sell |
-1,040
| Closed | -$198K | – | 2239 |
|
|
2023
Q2 | $198K | Buy |
+1,040
| New | +$198K | ﹤0.01% | 1331 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 2091 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 2105 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 2257 |
|
|
2022
Q1 | – | Sell |
-3,772
| Closed | -$640K | – | 2190 |
|
|
2021
Q4 | $640K | Buy |
3,772
+104
| +3% | +$17.6K | 0.02% | 821 |
|
|
2021
Q3 | $693 | Buy |
+3,668
| New | +$693 | 0.02% | 616 |
|
|
2020
Q1 | – | Sell |
-1,870
| Closed | -$215K | – | 510 |
|
|
2019
Q4 | $215K | Buy |
+1,870
| New | +$215K | 0.01% | 342 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 490 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 483 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 375 |
|
|
2018
Q3 | $751K | Buy |
+8,585
| New | +$751K | 0.35% | 73 |
|